ChrysCapital Acquires 70.68% Stake in Novartis India

Novartis India Limited (NIL) announced that ChrysCapital has acquired a controlling 70.68% stake in the company. This transaction marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector, aiming to build a leading branded-generics platform. Dr. Vikas Gupta has been appointed as the new Managing Director and Chief Executive Officer to lead NIL's next phase of growth. The company, with a legacy in therapeutic areas like pain management and neurosciences, will adopt a new name and corporate identity post-acquisition. ChrysCapital plans to leverage its expertise to strengthen NIL's market position.